Stayble Therapeutics AB (STABL) - Net Assets
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has net assets worth Skr6.92 Million SEK (≈ $744.92K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr8.62 Million ≈ $927.76K USD) and total liabilities (Skr1.70 Million ≈ $182.84K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STABL intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.92 Million |
| % of Total Assets | 80.29% |
| Annual Growth Rate | -5.07% |
| 5-Year Change | -82.61% |
| 10-Year Change | N/A |
| Growth Volatility | 72.52 |
Stayble Therapeutics AB - Net Assets Trend (2016–2025)
This chart illustrates how Stayble Therapeutics AB's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Stayble Therapeutics AB to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Stayble Therapeutics AB (2016–2025)
The table below shows the annual net assets of Stayble Therapeutics AB from 2016 to 2025. For live valuation and market cap data, see STABL market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr6.92 Million ≈ $744.92K |
+0.71% |
| 2024-12-31 | Skr6.87 Million ≈ $739.64K |
-58.37% |
| 2023-12-31 | Skr16.51 Million ≈ $1.78 Million |
+8.02% |
| 2022-12-31 | Skr15.28 Million ≈ $1.64 Million |
-61.61% |
| 2021-12-31 | Skr39.81 Million ≈ $4.28 Million |
+156.02% |
| 2020-12-31 | Skr15.55 Million ≈ $1.67 Million |
+5362.88% |
| 2019-12-31 | Skr-295.44K ≈ $-31.79K |
-104.15% |
| 2018-12-31 | Skr7.11 Million ≈ $765.43K |
-13.75% |
| 2017-12-31 | Skr8.25 Million ≈ $887.43K |
-25.44% |
| 2016-12-31 | Skr11.06 Million ≈ $1.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Stayble Therapeutics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 572420000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr8.37 Million | 120.88% |
| Other Comprehensive Income | Skr1.92 Million | 27.78% |
| Other Components | Skr3.56 Million | 51.43% |
| Total Equity | Skr6.92 Million | 100.00% |
Stayble Therapeutics AB Competitors by Market Cap
The table below lists competitors of Stayble Therapeutics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
$1.42 Million |
|
Sentul City Tbk
JK:BKSL
|
$1.42 Million |
|
Chinhung International Inc. Pfd. Series 2
KO:002787
|
$1.42 Million |
|
Labrador Technologies Inc
V:LTX
|
$1.43 Million |
|
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
|
$1.42 Million |
|
Mobius Investment Trust PLC
LSE:MMIT
|
$1.42 Million |
|
Ucommune International Ltd
NASDAQ:UK
|
$1.42 Million |
|
Aptitude Software Group PLC
LSE:APTD
|
$1.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stayble Therapeutics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,873,000 to 6,922,000, a change of 49,000 (0.7%).
- Net loss of 6,928,000 reduced equity.
- New share issuances of 7,190,000 increased equity.
- Other comprehensive income increased equity by 1,000.
- Other factors decreased equity by 214,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-6.93 Million | -100.09% |
| Share Issuances | Skr7.19 Million | +103.87% |
| Other Comprehensive Income | Skr1.00K | +0.01% |
| Other Changes | Skr-214.00K | -3.09% |
| Total Change | Skr- | 0.71% |
Book Value vs Market Value Analysis
This analysis compares Stayble Therapeutics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.17x to 1.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr1.24 | Skr0.21 | x |
| 2017-12-31 | Skr0.92 | Skr0.21 | x |
| 2018-12-31 | Skr0.80 | Skr0.21 | x |
| 2019-12-31 | Skr-0.06 | Skr0.21 | x |
| 2020-12-31 | Skr1.74 | Skr0.21 | x |
| 2021-12-31 | Skr2.80 | Skr0.21 | x |
| 2022-12-31 | Skr1.07 | Skr0.21 | x |
| 2023-12-31 | Skr0.64 | Skr0.21 | x |
| 2024-12-31 | Skr0.18 | Skr0.21 | x |
| 2025-12-31 | Skr0.12 | Skr0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stayble Therapeutics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-100.09%) is below the historical average (-84.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.88% | -3390.99% | 0.00x | 1.10x | Skr-2.31 Million |
| 2017 | -34.12% | 0.00% | 0.00x | 1.15x | Skr-3.64 Million |
| 2018 | -86.25% | -15293.69% | 0.00x | 1.27x | Skr-6.85 Million |
| 2019 | 0.00% | -1377242.37% | 0.00x | 0.00x | Skr-7.38 Million |
| 2020 | -99.61% | 0.00% | 0.00x | 1.16x | Skr-17.04 Million |
| 2021 | -30.25% | 0.00% | 0.00x | 1.10x | Skr-16.02 Million |
| 2022 | -160.49% | 0.00% | 0.00x | 1.25x | Skr-26.05 Million |
| 2023 | -143.79% | 0.00% | 0.00x | 1.31x | Skr-25.39 Million |
| 2024 | -180.68% | 0.00% | 0.00x | 1.35x | Skr-13.11 Million |
| 2025 | -100.09% | 0.00% | 0.00x | 1.25x | Skr-7.62 Million |
Industry Comparison
This section compares Stayble Therapeutics AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $159,185,570
- Average return on equity (ROE) among peers: -26.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stayble Therapeutics AB (STABL) | Skr6.92 Million | -10.88% | 0.25x | $1.42 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $5.16 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $41.03 Million |
| AcouSort AB (ACOU) | $376.48K | 28.69% | 1.44x | $9.52 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $103.60 Million |
| Alzinova AB (ALZ) | $105.53 Million | -12.38% | 0.06x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $233.17 Million | -15.43% | 0.02x | $46.62 Million |
| Annexin Pharmaceuticals AB (ANNX) | $15.57 Million | -63.12% | 0.51x | $9.23 Million |
| Alligator Bioscience AB (ATORX) | $41.44 Million | 0.00% | 0.15x | $11.36 Million |
| BioInvent International AB (BINV) | $49.01 Million | -36.81% | 0.66x | $163.58 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.39 Billion |
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.